caffeic acid phenethyl ester has been researched along with cabazitaxel in 1 studies
| Studies (caffeic acid phenethyl ester) | Trials (caffeic acid phenethyl ester) | Recent Studies (post-2010) (caffeic acid phenethyl ester) | Studies (cabazitaxel) | Trials (cabazitaxel) | Recent Studies (post-2010) (cabazitaxel) |
|---|---|---|---|---|---|
| 840 | 1 | 469 | 601 | 79 | 563 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Jin, C; Li, Z; Song, P; Song, W; Xuan, Z; Zhang, S; Zheng, S; Zhou, M | 1 |
1 other study(ies) available for caffeic acid phenethyl ester and cabazitaxel
| Article | Year |
|---|---|
Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caffeic Acids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; NF-kappa B; Pancreatic Neoplasms; Phenylethyl Alcohol; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2020 |